Virginia Tech® home

Virginia Tech Molecular Diagnostics Lab

Insert your title here

 

 

ADVANCING PRECISION ONCOLOGY

VIRGINIA TECH
MOLECULAR DIAGNOSTICS LAB

 

     

Advanced cancer genomics for Southwest Virginia and beyond.

The Molecular Diagnostics Laboratory at the Fralin Biomedical Research Institute is a CLIA-certified, CAP-accredited academic laboratory focused on the molecular characterization of cancer. Clinical testing, assay validation, and translational research operate within a single institutional structure and in coordination with regional healthcare partners.

A regional academic laboratory for cancer molecular diagnostics 

The laboratory integrates advanced genomic technologies, analytical rigor, and collaborative expertise to expand access to molecular characterization of cancer and support precision oncology research. Clinical molecular diagnostics, assay development and validation, and translational research are pursued within a single institutional structure. 

  

Neurobiology researcher views brain scan on monitor
FOR CLINICIANS Test menu ● Specimen submission ● Turnaround time ● Interpretive consultation
Molecular Diagnostic Lab worker
FOR RESEARCHERS Research-use platforms ● Collaboration pathways ● Assay development ● Trainee involvement
Woman hugging two children
FOR PATIENTS Testing is arranged by your clinician. General information is available for patients and family members.

 

Genomic Capabilities

The laboratory addresses multiple classes of genomic alteration in cancer through targeted next-generation sequencing, digital PCR, and, in a research-use context, long-read sequencing.

Alteration classes

  • Single-nucleotide variants (SNVs)
  • Small insertions and deletions (indels)
  • Copy-number alterations (CNAs)
  • Gene fusions
  • Structural variants
  • Microsatellite instability (MSI)*
  • Tumor mutational burden (TMB)*

Clinically reportable   The Oncomine Myeloid Assay is analytically validated and clinically reportable. Results carry clinical significance in myeloid malignancies as interpreted by the treating clinician.
Under analytical validation   The Oncomine Comprehensive Assay Plus is under analytical validation and is not currently clinically reportable.
Research-use platforms   Long-read sequencing on the Oxford Nanopore GridION and biomolecular interaction analysis on the Biacore 3000 are used in a research-use context and do not generate clinical reports.

* MSI and TMB are calculable from broad-panel sequencing. Their inclusion in the clinical menu is contingent on completion of validation of the corresponding assay.

  

  

cancer cells on slide
From specimen to report Accession Nucleic acid extraction and quality assessment Library preparation and sequencing (Ion Torrent Genexus with the Genexus Purification System) Bioinformatics analysis Clinical interpretation Sign-out and report delivery under the Medical Director's authority Interpretive consultation is available to ordering clinicians on request.
checking off on clipboard
Quality and accreditation The lab operates under CLIA certification. #49D0016288 for high-complexity clinical testing.

The laboratory holds accreditation under the CAP Laboratory Accreditation Program

Accreditation applies to the laboratory as a testing entity and does not, in itself, endorse any specific assay. Individual clinical assays are made available only after in-house analytical validation.
Blue ridge mountains
A regional resource The cancer landscape in Southwest Virginia reflects both national trends and regional factors. Cancer incidence and mortality rates are above state and national averages, particularly for lung, colorectal, breast, and endometrial cancers, shaped by regional epidemiological and socioeconomic conditions.

An academic molecular diagnostics laboratory located within the region shortens the geographic distance between specimen and analysis and situates molecular characterization within the same clinical and research community it serves.


Pipetting in lab
Research and assay development Assay development and validation. Analytical validation of laboratory-developed tests under CLIA and CAP frameworks.

Translational cancer genomics. Research-use characterization of tumor genomes, including long-read sequencing of structural variants and biomolecular interaction studies.

Implementation science. Studies of how molecular diagnostic testing is incorporated into clinical workflows in regional healthcare.

Research-use activities are governed separately from clinical testing operations and do not enter clinical care.

LEADERSHIP

ㅤ‎ ‎ 

 

MOLECULAR DIAGNOSTICS LAB NEWS